Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
48 studies found for:    "Epithelial-myoepithelial carcinoma"
Show Display Options
Rank Status Study
1 Recruiting A Study of ENMD-2076 in Ovarian Clear Cell Cancers
Condition: Ovarian Clear Cell Carcinoma
Intervention: Drug: ENMD-2076
2 Active, not recruiting Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Small Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Stage I Endometrial Carcinoma;   Stage IB Cervical Cancer;   Stage II Endometrial Carcinoma;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage III Endometrial Carcinoma;   Stage IVA Cervical Cancer
Interventions: Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography;   Drug: ferumoxtran-10;   Procedure: magnetic resonance imaging;   Procedure: diagnostic lymphadenectomy;   Procedure: lymph node biopsy
3 Recruiting Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
Conditions: Ovarian Cancer;   Adverse Effects
Intervention: Drug: Sunitinib
4 Recruiting A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Conditions: Ewing Sarcoma;   Gastrointestinal Tumor;   Germ Cell Tumor;   Hepatic Tumor;   Lymphoma;   Wilms Tumor;   Rhabdoid Tumor;   Clear Cell Carcinoma;   Renal Cell Carcinoma;   Melanoma;   Neuroblastoma;   Rhabdomyosarcoma;   Non-rhabdomyosarcoma
Interventions: Drug: alemtuzumab;   Drug: fludarabine;   Drug: sirolimus;   Drug: Busulfan;   Drug: melphalan;   Biological: stem cells
5 Unknown  Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)
Conditions: Endometrioid Carcinoma;   Clear Cell Carcinoma;   Endometriosis
Intervention:
6 Recruiting Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Stage IIIA Endometrial Carcinoma;   Stage IIIB Endometrial Carcinoma;   Stage IIIC Endometrial Carcinoma;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: metformin hydrochloride;   Other: placebo;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Other: questionnaire administration
7 Active, not recruiting Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Carcinoma;   Recurrent Endometrial Carcinoma
Intervention: Drug: brivanib alaninate
8 Active, not recruiting Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
Conditions: Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Stage IIIA Endometrial Carcinoma;   Stage IIIC Endometrial Carcinoma;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma
Interventions: Drug: doxorubicin hydrochloride;   Drug: cisplatin;   Drug: paclitaxel;   Biological: filgrastim;   Biological: pegfilgrastim
9 Active, not recruiting Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis
10 Completed Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Stage IIIA Endometrial Carcinoma;   Stage IIIB Endometrial Carcinoma;   Stage IIIC Endometrial Carcinoma;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma
Interventions: Drug: temsirolimus;   Other: laboratory biomarker analysis
11 Completed Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenoacanthoma;   Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma
Interventions: Drug: thalidomide;   Other: laboratory biomarker analysis
12 Completed
Has Results
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Stage I Endometrial Carcinoma;   Stage II Endometrial Carcinoma;   Stage III Endometrial Carcinoma;   Stage IV Endometrial Carcinoma
Interventions: Radiation: intensity-modulated radiation therapy;   Drug: cisplatin;   Biological: bevacizumab;   Drug: carboplatin;   Drug: paclitaxel
13 Active, not recruiting Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Conditions: Endometrial Adenoacanthoma;   Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Endometrial Stromal Sarcoma;   Recurrent Endometrial Carcinoma
Intervention: Biological: trebananib
14 Active, not recruiting Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
Conditions: Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Stage I Endometrial Carcinoma;   Stage II Endometrial Carcinoma;   Stage III Endometrial Carcinoma;   Stage IV Endometrial Carcinoma
Interventions: Drug: cisplatin;   Drug: paclitaxel;   Drug: carboplatin;   Radiation: brachytherapy
15 Recruiting Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Conditions: Endometrial Adenoacanthoma;   Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma
Interventions: Radiation: brachytherapy;   Radiation: 3-dimensional conformal radiation therapy;   Drug: cisplatin
16 Active, not recruiting Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma
Interventions: Biological: dalantercept;   Other: laboratory biomarker analysis
17 Active, not recruiting
Has Results
Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Recurrent Endometrial Carcinoma
Interventions: Drug: selumetinib;   Other: diagnostic laboratory biomarker analysis
18 Completed ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
Conditions: Non-Small-Cell Lung Carcinoma;   Renal Cell Carcinoma;   Pancreatic Cancer
Intervention: Drug: ABR-217620
19 Active, not recruiting AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
Condition: Advanced Renal Cell Carcinoma
Interventions: Drug: AMG 386;   Drug: Sorafenib
20 Completed Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Condition: Kidney Cancer
Interventions: Biological: aldesleukin;   Biological: bevacizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years